Views: 1,178 | Downloads:
20
| Responses: 0
XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
In Vitro Activity and Clinical Evaluation of Cefixime in Urinary Tract Infection
Thirty-five women with uncomplicated acute lower urinary tract infections proven by
significant pre-treatment bacteriuria (≥ I05CFU/ml) were treated with an oral dose of 100 mg
cefixime twice a day for seven days.
Thirty five patients included in this study were checked for response to treatment on the
last day of therapy, 7-14 days and 4 weeks post therapy. The clinical response and bacterial
eradication rate for cefixime were 91.4 per cent (32/35). The infecting organisms, E. coli and
Proteus mirabilis, were inhibited at MIC90= 0.5 and ≤ 0.03 µg/ml, and MBC = 1 and 0.06
µg/ml respectively. No adverse events were found in this study.
significant pre-treatment bacteriuria (≥ I05CFU/ml) were treated with an oral dose of 100 mg
cefixime twice a day for seven days.
Thirty five patients included in this study were checked for response to treatment on the
last day of therapy, 7-14 days and 4 weeks post therapy. The clinical response and bacterial
eradication rate for cefixime were 91.4 per cent (32/35). The infecting organisms, E. coli and
Proteus mirabilis, were inhibited at MIC90= 0.5 and ≤ 0.03 µg/ml, and MBC = 1 and 0.06
µg/ml respectively. No adverse events were found in this study.
Download:
PDF